ELOXX PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ELOXX PHARMACEUTICALS, INC. (ELOX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $95.00 thousand for the 3-month period ending 2026-06-30, per its S-1 filed 2026-09-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-09-11
- ELOXX PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $95.00K, a 493.75% increase year-over-year.
- ELOXX PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $46.00K, a 130.00% increase year-over-year.
- ELOXX PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $16.00K.
- ELOXX PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $20.00K.
- ELOXX PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $3.02M, a 67.04% decline from fiscal 2021.
- ELOXX PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $9.17M, a 5.78% increase from fiscal 2020.
- ELOXX PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $8.67M, a 23.55% decline from fiscal 2019.
- ELOXX PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2019 was $11.34M, a 15.21% decline from fiscal 2018.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $95.00K S-1 · filed 2026-09-11 | $141.00K derived: sum of 2 quarters · filed 2026-09-11 | ||
| 2026-03-31 | $46.00K S-1 · filed 2026-09-11 | |||
| 2025-12-31 | $235.00K S-1 · filed 2026-09-11 | |||
| 2025-06-30 | $16.00K S-1 · filed 2026-09-11 | $36.00K derived: sum of 2 quarters · filed 2026-09-11 | ||
| 2025-03-31 | $20.00K S-1 · filed 2026-09-11 | |||
| 2024-12-31 | $541.00K S-1 · filed 2026-09-11 | |||
| 2023-12-31 | $1.97M S-1 · filed 2026-09-11 | |||
| 2023-09-30 | $418.00K 10-Q · filed 2023-11-13 | $1.03M derived: sum of 2 quarters · filed 2023-11-13 | $1.63M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2023-06-30 | $610.00K 10-Q · filed 2023-11-13 | $1.21M derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2023-03-31 | $597.00K 10-Q · filed 2023-11-13 | |||
| 2022-12-31 | $3.02M 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $714.00K 10-Q · filed 2023-11-13 | $1.46M derived: sum of 2 quarters · filed 2023-11-13 | $2.38M derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $744.00K 10-Q · filed 2023-11-13 | $1.67M derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $922.00K 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $9.17M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $2.22M 10-Q · filed 2022-11-10 | $6.26M derived: sum of 2 quarters · filed 2022-11-10 | $7.57M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $4.04M 10-Q · filed 2022-11-10 | $5.34M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $1.31M 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $8.67M 10-K · filed 2022-03-30 | |||
| 2020-09-30 | $1.42M 10-Q · filed 2021-11-08 | $3.39M derived: sum of 2 quarters · filed 2021-11-08 | $7.39M derived: sum of 3 quarters · filed 2021-11-08 | |
| 2020-06-30 | $1.98M 10-Q · filed 2021-11-08 | $5.97M derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2020-03-31 | $4.00M 10-Q · filed 2021-11-08 | |||
| 2019-12-31 | $11.34M 10-K · filed 2022-03-30 | |||
| 2019-09-30 | $2.96M 10-Q · filed 2020-11-06 | $5.97M derived: sum of 2 quarters · filed 2020-11-06 | $8.63M derived: sum of 3 quarters · filed 2020-11-06 | $12.39M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $3.02M 10-Q · filed 2020-11-06 | $5.67M derived: sum of 2 quarters · filed 2020-11-06 | $9.44M derived: sum of 3 quarters · filed 2021-03-12 | $12.13M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $2.66M 10-Q · filed 2020-11-06 | $6.42M derived: sum of 2 quarters · filed 2021-03-12 | $9.12M derived: sum of 3 quarters · filed 2021-03-12 | $15.29M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $3.76M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $6.46M derived: sum of 2 quarters · filed 2021-03-12 | $12.63M derived: sum of 3 quarters · filed 2021-03-12 | $13.37M 10-K · filed 2021-03-12 |
| 2018-09-30 | $2.69M 10-Q · filed 2019-11-06 | $8.87M derived: sum of 2 quarters · filed 2019-11-06 | $9.61M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $6.18M 10-Q · filed 2019-11-06 | $6.91M 10-Q · filed 2018-08-10 | ||
| 2018-03-31 | $735.00K 10-Q · filed 2019-11-06 | |||
| 2017-12-31 | $101.00K 10-K · filed 2020-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |